Shots:

• Under the collaboration, the companies will jointly develop CDx solutions for the innovative assets which are being developed under I-Mab to accelerate the R&D process of innovative biologics with cutting-edge diagnosis and treatment technologies
• The collaboration will complement I-Mab's efforts and accelerate the clinical R&D of its innovative pipeline with the addition of Roche Diagnostics' CDx technology to provide transformative medicines for cancer patients globally and in China
• I-Mab plans to expands its global footprint beyond Shanghai (HQ), Beijing, Hangzhou, Guangzhou, Lishui, and Hong Kong in China & Maryland, San Diego (US)

  Ref: PR Newswire | Image: I-Mab